ESR1 and breast cancer: Despite advances in the treatment of ER+ and HER2+ subtypes of BC in the past decades, there is still a lack of reliable biomarkers with better precision than the existing ones currently used to predict treatment response of subtypes of BC, especially for triple-negative BC.